Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in
patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine
how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will
also evaluate potential anti-tumor activity of IPI-504.